Dice Therapeutics Inc Quick Ratio (DICE) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Dice Therapeutics Inc   (NASDAQ: DICE)

Dice Therapeutics Inc 's Quick Ratio

DICE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 25.69 below Dice Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 28 other companies have achieved higher Quick Ratio than Dice Therapeutics Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 76 to 112.

Explain Quick Ratio?
How much Cash & cash equivalents DICE´s has?
What are DICE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DICE Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 70.49 % 16.54 % 204.26 % -8.29 % 9.55 %
Y / Y Cash & cash equivalent Change 87.22 % 82.88 % 79.83 % -20.57 % 332.89 %
Quick Ratio MRQ 25.69 32.16 37.91 22.86 23.39
DICE's Total Ranking # 112 # 76 # 74 # 161 # 133
Seq. Current Liabilities Change 19.31 % 13.81 % 29.87 % -3.32 % -18.44 %
Seq. Cash & cash equivalent Change -4.72 % -3.43 % 115.38 % -5.53 % -6.93 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 42
Overall Market # 112


Quick Ratio Statistics
High Average Low
37.91 27.28 20.5
(Dec 31 2022)   (Mar 31 2022)




Financial Statements
Dice Therapeutics Inc 's Current Liabilities $ 21 Millions Visit DICE's Balance sheet
Dice Therapeutics Inc 's Cash & cash equivalent $ 528 Millions Visit DICE's Balance sheet
Source of DICE's Sales Visit DICE's Sales by Geography


Cumulative Dice Therapeutics Inc 's Quick Ratio

DICE's Quick Ratio for the trailling 12 Months

DICE Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 45.03 % 28.99 % 86.93 % 83.3 % 304.57 %
Y / Y Cash & cash equivalent TTM Growth 55.09 % 63.92 % 98.05 % 192.22 % 1802.65 %
Quick Ratio TTM 29.77 29.89 26.57 26.93 27.84
Total Ranking TTM # 2624 # 2632 # 2715 # 80 # 118
Seq. Current Liabilities TTM Growth 15.15 % 4.56 % 23.38 % -2.37 % 2.42 %
Seq. Cash & cash equivalent TTM Growth 14.67 % 17.62 % 21.76 % -5.57 % 21.21 %

Quick ratio ranking by company, industry and sector >> Back to DICE Financial Strength Comparisons >> Go to Compare DICE Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2023 to $20.57 millions, cumulative Quick Ratio decreased to 29.77 above the DICE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 492 other companies have achieved higher Quick Ratio than Dice Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2624, from total ranking during the twelve months ending first quarter 2023 at 2632.

Explain Quick Ratio?
How much Cash & cash equivalents DICE´s has?
What are DICE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 493
Healthcare Sector # 937
Within the Market # 2624


trailing twelve months Quick Ratio Statistics
High Average Low
29.89 23.66 13.2
(Mar 31 2023)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Moonlake Immunotherapeutics  70.33 $ 501.787  Millions$ 7.135  Millions
Third Harmonic Bio Inc   65.86 $ 278.132  Millions$ 4.223  Millions
Tao Synergies Inc   64.85 $ 32.899  Millions$ 0.507  Millions
Acelyrin Inc   60.94 $ 556.169  Millions$ 9.127  Millions
Ionis Pharmaceuticals Inc   51.75 $ 7,943.844  Millions$ 153.498  Millions
Neurogene Inc   48.45 $ 164.107  Millions$ 3.387  Millions
Nuvation Bio Inc   47.04 $ 630.900  Millions$ 13.413  Millions
Merrimack Pharmaceuticals Inc  46.15 $ 18.968  Millions$ 0.411  Millions
Xbiotech Inc   46.02 $ 204.771  Millions$ 4.450  Millions
Tyra Biosciences Inc   43.00 $ 232.413  Millions$ 5.405  Millions
Morphic Holding inc   41.07 $ 731.356  Millions$ 17.809  Millions
Altimmune inc   39.64 $ 159.954  Millions$ 4.035  Millions
Structure Therapeutics Inc   39.41 $ 224.587  Millions$ 5.699  Millions
Disc Medicine Inc   39.00 $ 377.602  Millions$ 9.683  Millions
Atea Pharmaceuticals Inc   37.63 $ 608.062  Millions$ 16.159  Millions
Karuna Therapeutics Inc   37.21 $ 1,436.510  Millions$ 38.603  Millions
Rafael Holdings Inc  36.93 $ 79.212  Millions$ 2.145  Millions
Greenwich Lifesciences Inc   36.29 $ 10.944  Millions$ 0.302  Millions
Jade Biosciences Inc   33.96 $ 239.522  Millions$ 7.054  Millions
Pharvaris N v   33.95 $ 195.674  Millions$ 5.763  Millions
Astria Therapeutics Inc   30.76 $ 202.958  Millions$ 6.598  Millions
Viking Therapeutics Inc   29.85 $ 392.920  Millions$ 13.164  Millions
Adc Therapeutics Sa  29.72 $ 347.510  Millions$ 11.691  Millions
Akero Therapeutics Inc   29.60 $ 639.444  Millions$ 21.602  Millions
Atossa Therapeutics Inc   28.61 $ 99.500  Millions$ 3.478  Millions
Climb Bio Inc   28.37 $ 102.633  Millions$ 3.618  Millions
Minerva Neurosciences Inc   27.15 $ 51.797  Millions$ 1.908  Millions
Theseus Pharmaceuticals Inc   27.10 $ 208.205  Millions$ 7.682  Millions
Verona Pharma Plc  26.02 $ 270.727  Millions$ 10.404  Millions
Dice Therapeutics Inc   25.69 $ 528.383  Millions$ 20.571  Millions

Date modified: 2026-08-29T17:45:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.